{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:54:55Z","timestamp":1789732495307,"version":"4.0.1"},"reference-count":129,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>This guideline is the first Iranian guideline developed for the diagnosis, management, and treatment of hyperlipidemia in adults. The members of the guideline developing group (GDG) selected 9 relevant clinical questions and provided recommendations or suggestions to answer them based on the latest scientific evidence. Recommendations include the low-density lipoprotein cholesterol (LDL-C) threshold for starting drug treatment in adults lacking comorbidities was determined to be over 190 mg\/dL and the triglyceride (TG) threshold had to be &gt;500 mg\/dl. In addition to perform fasting lipid profile tests at the beginning and continuation of treatment, while it was suggested to perform cardiovascular diseases (CVDs) risk assessment using valid Iranian models. Some recommendations were also provided on lifestyle modification as the first therapeutic intervention. Statins were recommended as the first line of drug treatment to reduce LDL-C, and if its level was high despite the maximum allowed or maximum tolerated drug treatment, combined treatment with ezetimibe, proprotein convertase subtilisin\/kexin type 9 inhibitors, or bile acid sequestrants was suggested. In adults with hypertriglyceridemia, pharmacotherapy with statin or fibrate was recommended. The target of drug therapy in adults with increased LDL-C without comorbidities and risk factors was considered an LDL-C level of &lt;130 mg\/dl, and in adults with increased TG without comorbidities and risk factors, TG levels of &lt;200 mg\/dl. In this guideline, specific recommendations and suggestions were provided for the subgroups of the general population, such as those with CVD, stroke, diabetes, chronic kidney disease, elderly, and women.<\/jats:p>","DOI":"10.4103\/jrms.jrms_318_23","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T14:39:42Z","timestamp":1711636782000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["First Iranian guidelines for the diagnosis, management, and treatment of hyperlipidemia in adults"],"prefix":"10.4103","volume":"29","author":[{"given":"Fahimeh Bagheri","family":"Kholenjani","sequence":"first","affiliation":[{"name":"Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahla","family":"Shahidi","sequence":"additional","affiliation":[{"name":"Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golnaz","family":"Vaseghi","sequence":"additional","affiliation":[{"name":"Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Ashoorion","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods Evidence and Impact, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizal","family":"Sarrafzadegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansour","family":"Siavash","sequence":"additional","affiliation":[{"name":"Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Heidarpour","sequence":"additional","affiliation":[{"name":"Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrzad","family":"Shahidi","sequence":"additional","affiliation":[{"name":"Isfahan Kidney Diseases Research Center, Internal Medicine Department, Khorshid Hospital, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoumeh","family":"Sadeghi","sequence":"additional","affiliation":[{"name":"Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noushin","family":"Mohammadifard","sequence":"additional","affiliation":[{"name":"Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoumeh","family":"Jorjani","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid Ghayour","family":"Mobarhan","sequence":"additional","affiliation":[{"name":"Iranian UNESCO Center of Excellence for Human Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davood","family":"Shafie","sequence":"additional","affiliation":[{"name":"Heart Failure Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Farshidi","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Center, Hormozgan University of Medical Sciences, BandarAbbas, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariborz","family":"Khorvash","sequence":"additional","affiliation":[{"name":"Isfahan Neurosciences Research Center, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojdeh","family":"Ghabaei","sequence":"additional","affiliation":[{"name":"Iranian Tissue Bank and Preparation Research Centre, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Teimouri-Jervekani","sequence":"additional","affiliation":[{"name":"Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojgan","family":"Mortazavi","sequence":"additional","affiliation":[{"name":"Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valiollah","family":"Hajhashemi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Roshanravan","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Yazdanpanah","sequence":"additional","affiliation":[{"name":"Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Davari","sequence":"additional","affiliation":[{"name":"Department of Pharmacoeconomics and Pharmaceutical Administration, Pharmaceutical Management and Economic Research Center, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Fatemi","sequence":"additional","affiliation":[{"name":"Department of Pharmacoeconomics and Pharmaceutical Administration, Pharmaceutical Management and Economic Research Center, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaheh","family":"Khorasani","sequence":"additional","affiliation":[{"name":"Department of Surgery, McGill University Health Center, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Hoseinkhani","sequence":"additional","affiliation":[{"name":"Deputy of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaheh","family":"Zarean","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Ahmadi","sequence":"additional","affiliation":[{"name":"Pediatric Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam Eghbali","family":"Babadi","sequence":"additional","affiliation":[{"name":"Nursing and Midwifery Care Research Center, Faculty of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmadreza","family":"Assareh","sequence":"additional","affiliation":[{"name":"Atherosclerosis Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Shadmani","sequence":"additional","affiliation":[{"name":"Iranian Diabetes Society, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Kojuri","sequence":"additional","affiliation":[{"name":"Clinical Education Research Center, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farimah","family":"Shirani","sequence":"additional","affiliation":[{"name":"Nursing and Midwifery Care Research Center, Faculty of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojgan","family":"Sanjari","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahimeh","family":"Haghighatdoost","sequence":"additional","affiliation":[{"name":"Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razieh","family":"Hassannejad","sequence":"additional","affiliation":[{"name":"Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Hashemi","sequence":"additional","affiliation":[{"name":"Metabolic Liver Disease Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hassan","family":"Moaddab","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaleh","family":"Gheisari","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Isfahan Research Center of Kidney Diseases, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahar","family":"Dehghan","sequence":"additional","affiliation":[{"name":"Pediatric Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitra","family":"Naseri","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nosrat","family":"Ghaemi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, Akbar Hospital, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fereidoun","family":"Noohi","sequence":"additional","affiliation":[{"name":"Iranian Network of Cardiovascular Research, Tehran, Iran"},{"name":"Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AliAkbar","family":"Haghdoost","sequence":"additional","affiliation":[{"name":"HIV\/STI Surveillance Research Center and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Salehi-Abargouei","sequence":"additional","affiliation":[{"name":"Research Center for Food Hygiene and Safety, Yazd Cardiovascular Research Center, Non-communicable Disease Research Institute, Department of Nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Beigrezaie","sequence":"additional","affiliation":[{"name":"Department of Global Public Health and Bioethics, Julius Center, University Medical Center (UMC) Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Doosti-Irani","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health, Research Center for Health Sciences, Hamadan University of Medical Sciences, Hamadan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Ramezani-Jolfaie","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, School of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijan","family":"Eraj","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahin","family":"Hashemipour","sequence":"additional","affiliation":[{"name":"Metabolic Liver Disease Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebrahim","family":"Nematipour","sequence":"additional","affiliation":[{"name":"Department of Cardiology, School of Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Rafieian","family":"Kopaei","sequence":"additional","affiliation":[{"name":"Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,3]]},"reference":[{"key":"R2-20240830","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.atherosclerosis.2013.11.031","article-title":"An international atherosclerosis society position paper: Global recommendations for the management of dyslipidemia: Executive summary","volume":"232","author":"Grundy","year":"2014","journal-title":"Atherosclerosis"},{"key":"R3-20240830","first-page":"373","article-title":"Prevalence of dyslipidemia in Iran: A systematic review and meta-analysis study","volume":"5","author":"Tabatabaei-Malazy","year":"2014","journal-title":"Int J Prev Med"},{"key":"R4-20240830","doi-asserted-by":"crossref","first-page":"503","DOI":"10.4103\/1735-1995.163979","article-title":"Prevalence of dyslipidemia in Iranian children and adolescents: A systematic review","volume":"20","author":"Hovsepian","year":"2015","journal-title":"J Res Med Sci"},{"key":"R5-20240830","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5334\/gh.1097","article-title":"The cost-effectiveness of hyperlipidemia medication in low- and middle-income countries: A review","volume":"17","author":"Husain","year":"2022","journal-title":"Glob Heart"},{"key":"R6-20240830","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: Executive summary: A report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R7-20240830","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ypmed.2019.02.003","article-title":"The importance of cholesterol follow-up testing under current statin treatment guidelines","volume":"121","author":"Dansinger","year":"2019","journal-title":"Prev Med"},{"key":"R8-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta191000","article-title":"Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: A systematic review with statistical and cost-effectiveness modelling","volume":"19","author":"Perera","year":"2015","journal-title":"Health Technol Assess"},{"key":"R9-20240830","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1016\/j.amjmed.2019.04.002","article-title":"Association between lipid testing and statin adherence in the veterans affairs health system","volume":"132","author":"Jia","year":"2019","journal-title":"Am J Med"},{"key":"R10-20240830","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.amjcard.2019.12.030","article-title":"Impact of lipid monitoring on treatment intensification of cholesterol lowering therapies (from the Veterans affairs healthcare system)","volume":"125","author":"Jia","year":"2020","journal-title":"Am J Cardiol"},{"key":"R11-20240830","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1017\/S1368980010002399","article-title":"Double burden of nutritional disorders in young Iranian children: Findings of a nationwide screening survey","volume":"14","author":"Motlagh","year":"2011","journal-title":"Public Health Nutr"},{"key":"R12-20240830","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1751-7176.2008.08329.x","article-title":"Barriers to optimal hypertension control","volume":"10","author":"Ogedegbe","year":"2008","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R13-20240830","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"290","author":"Mach","year":"2019","journal-title":"Atherosclerosis"},{"key":"R14-20240830","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jacc.2019.03.009","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: Executive summary: A report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R15-20240830","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/CIR.0b013e31828f8a94","article-title":"American Heart Association guide for improving cardiovascular health at the community level, 2013 update: A scientific statement for public health practitioners, healthcare providers, and health policy makers","volume":"127","author":"Pearson","year":"2013","journal-title":"Circulation"},{"key":"R16-20240830","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"R17-20240830","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"R18-20240830","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"HPS3\/TIMI55-REVEAL","year":"2017","journal-title":"N Engl J Med"},{"key":"R19-20240830","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.amjcard.2016.02.011","article-title":"A VOYAGER meta-analysis of the impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia","volume":"117","author":"Karlson","year":"2016","journal-title":"Am J Cardiol"},{"key":"R20-20240830","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: A meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R21-20240830","doi-asserted-by":"crossref","first-page":"e210661","DOI":"10.1001\/jamanetworkopen.2021.0661","article-title":"Patient preference distribution for use of statin therapy","volume":"4","author":"Brodney","year":"2021","journal-title":"JAMA Netw Open"},{"key":"R22-20240830","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","article-title":"2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"R23-20240830","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1210\/endrev\/bnab037","article-title":"A modern approach to dyslipidemia","volume":"43","author":"Berberich","year":"2022","journal-title":"Endocr Rev"},{"key":"R24-20240830","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.27157","article-title":"Spectrum of statin hepatotoxicity: Experience of the drug-induced liver injury network","volume":"60","author":"Russo","year":"2014","journal-title":"Hepatology"},{"key":"R25-20240830","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ccl.2015.02.005","article-title":"Statins and the liver","volume":"33","author":"Herrick","year":"2015","journal-title":"Cardiol Clin"},{"key":"R26-20240830","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jacl.2014.02.011","article-title":"An assessment by the statin liver safety task force: 2014 update","volume":"8","author":"Bays","year":"2014","journal-title":"J Clin Lipidol"},{"key":"R27-20240830","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jfma.2018.11.017","article-title":"2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance","volume":"118","author":"Chien","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"R28-20240830","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: Impact on statin therapy-European Atherosclerosis Society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"R29-20240830","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.cjca.2016.01.003","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian consensus working group update (2016)","volume":"32","author":"Mancini","year":"2016","journal-title":"Can J Cardiol"},{"key":"R30-20240830","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the statin muscle safety task force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J Clin Lipidol"},{"key":"R31-20240830","doi-asserted-by":"crossref","first-page":"89C","DOI":"10.1016\/j.amjcard.2006.02.030","article-title":"Final conclusions and recommendations of the national lipid association statin safety assessment task force","volume":"97","author":"McKenney","year":"2006","journal-title":"Am J Cardiol"},{"key":"R32-20240830","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrcardio.2015.28","article-title":"Cardiovascular risk assessment: A global perspective","volume":"12","author":"Zhao","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"R33-20240830","doi-asserted-by":"crossref","first-page":"c2197","DOI":"10.1136\/bmj.c2197","article-title":"Unintended effects of statins in men and women in England and Wales: Population based cohort study using the QResearch database","volume":"340","author":"Hippisley-Cox","year":"2010","journal-title":"BMJ"},{"key":"R34-20240830","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.amjmed.2005.02.008","article-title":"Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization","volume":"118","author":"Charles","year":"2005","journal-title":"Am J Med"},{"key":"R35-20240830","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijcard.2021.03.007","article-title":"Clinical impact and room for improvement of intensity and adherence to lipid lowering therapy: Five years of clinical follow-up from 164,565 post-myocardial infarction patients","volume":"332","author":"Schiele","year":"2021","journal-title":"Int J Cardiol"},{"key":"R36-20240830","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jacl.2022.05.003","article-title":"Adherence to lipid monitoring and its impact on treat intensification of LDL-C lowering therapies at an urban academic medical center","volume":"16","author":"Tran","year":"2022","journal-title":"J Clin Lipidol"},{"key":"R37-20240830","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/ehjqcco\/qcab024","article-title":"High-statin adherence over 5 years of follow-up is associated with improved cardiovascular outcomes in patients with atherosclerotic cardiovascular disease: Results from the IMPRES study","volume":"8","author":"May","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"R38-20240830","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"R39-20240830","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00392-006-0403-x","article-title":"Low density lipoprotein cholesterol, statins and cardiovascular events: A meta-analysis","volume":"95","author":"Genser","year":"2006","journal-title":"Clin Res Cardiol"},{"key":"R40-20240830","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/qjmed\/hcq165","article-title":"Efficacy and safety of statin treatment for cardiovascular disease: A network meta-analysis of 170,255 patients from 76 randomized trials","volume":"104","author":"Mills","year":"2011","journal-title":"QJM"},{"key":"R41-20240830","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"},{"key":"R42-20240830","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"R43-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2021.09.010","article-title":"A systematic review and meta-analysis on the effects of statins on pregnancy outcomes","volume":"336","author":"Vahedian-Azimi","year":"2021","journal-title":"Atherosclerosis"},{"key":"R44-20240830","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/MOL.0000000000000790","article-title":"Management of familial hypercholesterolemia in pregnancy","volume":"32","author":"Graham","year":"2021","journal-title":"Curr Opin Lipidol"},{"key":"R45-20240830","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.amjcard.2008.10.029","article-title":"Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged<65 versus>or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study)","volume":"103","author":"Tikkanen","year":"2009","journal-title":"Am J Cardiol"},{"key":"R46-20240830","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"R47-20240830","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/hrt.2009.172619","article-title":"Lipid re-screening: What is the best measure and interval?","volume":"96","author":"Takahashi","year":"2010","journal-title":"Heart"},{"key":"R48-20240830","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-148-9-200805060-00005","article-title":"LIPID Study Investigators. Monitoring cholesterol levels: Measurement error or true change?","volume":"148","author":"Glasziou","year":"2008","journal-title":"Ann Intern Med"},{"key":"R49-20240830","article-title":"Qualitative Evaluation Report of Values and Preferences of Dyslipidemia Patients","year":"2021"},{"key":"R50-20240830","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: The Framingham heart study","volume":"117","author":"D\u2019Agostino","year":"2008","journal-title":"Circulation"},{"key":"R51-20240830","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology\/American Heart Association task force on practice guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R52-20240830","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s11886-022-01706-4","article-title":"How much lowering of blood pressure is required to prevent cardiovascular disease in patients with and without previous cardiovascular disease?","volume":"24","author":"Canoy","year":"2022","journal-title":"Curr Cardiol Rep"},{"key":"R53-20240830","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/hrt.2006.108167","article-title":"Adding social deprivation and family history to cardiovascular risk assessment: The ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC)","volume":"93","author":"Woodward","year":"2007","journal-title":"Heart"},{"key":"R54-20240830","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/bmj.39261.471806.55","article-title":"Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: Prospective open cohort study","volume":"335","author":"Hippisley-Cox","year":"2007","journal-title":"BMJ"},{"key":"R55-20240830","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/hc0302.102575","article-title":"Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular M\u00fcnster (PROCAM) study","volume":"105","author":"Assmann","year":"2002","journal-title":"Circulation"},{"key":"R56-20240830","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S2213-8587(15)00081-9","article-title":"A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): A pooled analysis of prospective cohorts and health examination surveys","volume":"3","author":"Hajifathalian","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R57-20240830","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0140-6736(05)70240-3","article-title":"Treatment with drugs to lower blood pressure and blood cholesterol based on an individual\u2019s absolute cardiovascular risk","volume":"365","author":"Jackson","year":"2005","journal-title":"Lancet"},{"key":"R58-20240830","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5334\/gh.890","article-title":"Developing non-laboratory cardiovascular risk assessment charts and validating laboratory and non-laboratory-based models","volume":"16","author":"Hassannejad","year":"2021","journal-title":"Glob Heart"},{"key":"R59-20240830","doi-asserted-by":"crossref","first-page":"e0189389","DOI":"10.1371\/journal.pone.0189389","article-title":"PARS risk charts: A 10-year study of risk assessment for cardiovascular diseases in Eastern Mediterranean Region","volume":"12","author":"Sarrafzadegan","year":"2017","journal-title":"PLoS One"},{"key":"R60-20240830","article-title":"Guideline for the Pharmacological Treatment of Hypertension in Adults: Web Annex A: Summary of Evidence","year":"2021","journal-title":"World Health Organization"},{"key":"R61-20240830","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/1741826711407705","article-title":"Survey of physicians\u2019 practices in the control of cardiovascular risk factors: The EURIKA study","volume":"19","author":"Dallongeville","year":"2012","journal-title":"Eur J Prev Cardiol"},{"key":"R62-20240830","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ccell.2008.03.014","article-title":"Cardiovascular risk assessment and hyperlipidemia","volume":"20","author":"Becker","year":"2008","journal-title":"Crit Care Nurs Clin North Am"},{"key":"R63-20240830","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archinternmed.2009.38","article-title":"A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease","volume":"169","author":"Mente","year":"2009","journal-title":"Arch Intern Med"},{"key":"R64-20240830","article-title":"Global status report on noncommunicable diseases 2014","year":"2014","journal-title":"World Health Organization"},{"key":"R65-20240830","doi-asserted-by":"crossref","first-page":"e1003543","DOI":"10.1371\/journal.pmed.1003543","article-title":"Comparative effect of physical exercise versus statins on improving arterial stiffness in patients with high cardiometabolic risk: A network meta-analysis","volume":"18","author":"Cavero-Redondo","year":"2021","journal-title":"PLoS Med"},{"key":"R66-20240830","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2468-2667(18)30135-X","article-title":"Dietary carbohydrate intake and mortality: A prospective cohort study and meta-analysis","volume":"3","author":"Seidelmann","year":"2018","journal-title":"Lancet Public Health"},{"key":"R67-20240830","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1194\/jlr.P085522","article-title":"Effects of oils and solid fats on blood lipids: A systematic review and network meta-analysis","volume":"59","author":"Schwingshackl","year":"2018","journal-title":"J Lipid Res"},{"key":"R68-20240830","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/archinte.166.3.285","article-title":"Effects of low-carbohydrate versus low-fat diets on weight loss and cardiovascular risk factors: A meta-analysis of randomized controlled trials","volume":"166","author":"Nordmann","year":"2006","journal-title":"Arch Intern Med"},{"key":"R69-20240830","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/ajcn\/56.2.320","article-title":"Effects of weight reduction on blood lipids and lipoproteins: A meta-analysis","volume":"56","author":"Dattilo","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"R70-20240830","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ahj.2012.04.014","article-title":"Exercise effects on lipids in persons with varying dietary patterns-does diet matter if they exercise? Responses in studies of a targeted risk reduction intervention through defined exercise I","volume":"164","author":"Huffman","year":"2012","journal-title":"Am Heart J"},{"key":"R71-20240830","doi-asserted-by":"crossref","first-page":"d636","DOI":"10.1136\/bmj.d636","article-title":"Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: Systematic review and meta-analysis of interventional studies","volume":"342","author":"Brien","year":"2011","journal-title":"BMJ"},{"key":"R72-20240830","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.2337\/dc09-0266","article-title":"Effects of a plant-based high-carbohydrate\/high-fiber diet versus high-monounsaturated fat\/low-carbohydrate diet on postprandial lipids in type 2 diabetic patients","volume":"32","author":"De Natale","year":"2009","journal-title":"Diabetes Care"},{"key":"R73-20240830","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0140-6736(18)31310-2","article-title":"Alcohol use and burden for 195 countries and territories, 1990\u20132016: A systematic analysis for the global burden of disease study 2016","volume":"392","author":"Yasin","year":"2018","journal-title":"Lancet"},{"key":"R74-20240830","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.1016\/S2468-2667(18)30200-7","article-title":"The effect of socioeconomic deprivation on the association between an extended measurement of unhealthy lifestyle factors and health outcomes: A prospective analysis of the UK Biobank cohort","volume":"3","author":"Foster","year":"2018","journal-title":"Lancet Public Health"},{"key":"R75-20240830","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0140-6736(18)31310-2","article-title":"Alcohol use and burden for 195 countries and territories, 1990-2016: A systematic analysis for the global burden of disease study 2016","volume":"392","author":"Griswold","year":"2018","journal-title":"Lancet"},{"key":"R76-20240830","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"R77-20240830","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"R78-20240830","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: A meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","year":"2019","journal-title":"Lancet"},{"key":"R79-20240830","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jacc.2014.06.1186","article-title":"A systematic examination of the 2013 ACC\/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease","volume":"64","author":"Karmali","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R80-20240830","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jama.2014.2630","article-title":"Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations","volume":"311","author":"Muntner","year":"2014","journal-title":"JAMA"},{"key":"R81-20240830","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/1479164112436403","article-title":"Global cardiovascular disease risk assessment in United States adults with diabetes","volume":"9","author":"Wong","year":"2012","journal-title":"Diab Vasc Dis Res"},{"key":"R82-20240830","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"R83-20240830","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"R84-20240830","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/dc05-2415","article-title":"Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN)","volume":"29","author":"Knopp","year":"2006","journal-title":"Diabetes Care"},{"key":"R85-20240830","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2337\/diacare.28.5.1151","article-title":"Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial \u2013 Lipid-lowering arm (ASCOT-LLA)","volume":"28","author":"Sever","year":"2005","journal-title":"Diabetes Care"},{"key":"R86-20240830","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2165\/11638240-000000000-00000","article-title":"Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: A meta-analysis","volume":"72","author":"de Vries","year":"2012","journal-title":"Drugs"},{"key":"R87-20240830","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.recesp.2020.05.034","article-title":"Diagnostic yield of sequencing familial hypercholesterolemia genes in individuals with primary hypercholesterolemia","volume":"74","author":"Lamiquiz-Moneo","year":"2021","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"R88-20240830","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/CIRCULATIONAHA.116.022335","article-title":"Long-term risk of atherosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotype","volume":"134","author":"Perak","year":"2016","journal-title":"Circulation"},{"key":"R89-20240830","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.116.023007","article-title":"Prognosis of patients with familial hypercholesterolemia after acute coronary syndromes","volume":"134","author":"Nanchen","year":"2016","journal-title":"Circulation"},{"key":"R90-20240830","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1161\/CIRCULATIONAHA.117.027966","article-title":"Low-Density lipoprotein cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg\/dL or above: Analyses from the WOSCOPS (west of Scotland coronary prevention study) 5-year randomized trial and 20-year observational follow-up","volume":"136","author":"Vallejo-Vaz","year":"2017","journal-title":"Circulation"},{"key":"R91-20240830","doi-asserted-by":"crossref","first-page":"a2423","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: A long term cohort study","volume":"337","author":"Versmissen","year":"2008","journal-title":"BMJ"},{"key":"R92-20240830","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: A meta-analysis of individual participant data from 28 randomised trials","volume":"4","author":"Herrington","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R93-20240830","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.2015.15629","article-title":"Statins for prevention of cardiovascular disease in adults: Evidence report and systematic review for the US preventive services task force","volume":"316","author":"Chou","year":"2016","journal-title":"JAMA"},{"key":"R94-20240830","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/CIRCOUTCOMES.111.000071","article-title":"Comparative tolerability and harms of individual statins: A study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials","volume":"6","author":"Naci","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R95-20240830","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/j.1524-4733.2008.00354.x","article-title":"Statin cost-effectiveness comparisons using real-world effectiveness data: Formulary implications","volume":"11","author":"Ohsfeldt","year":"2008","journal-title":"Value Health"},{"key":"R96-20240830","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/M14-1430","article-title":"Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States","volume":"162","author":"Odden","year":"2015","journal-title":"Ann Intern Med"},{"key":"R97-20240830","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5694\/j.1326-5377.2004.tb05891.x","article-title":"Statin prescribing in Australia: Socioeconomic and sex differences. A cross-sectional study","volume":"180","author":"Stocks","year":"2004","journal-title":"Med J Aust"},{"key":"R98-20240830","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1365-2125.2005.02494.x","article-title":"Socioeconomic gradient in use of statins among Danish patients: Population-based cross-sectional study","volume":"60","author":"Thomsen","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"R99-20240830","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.cjco.2020.07.002","article-title":"Barriers and facilitators to using statins: A qualitative study with patients and family physicians","volume":"2","author":"Butalia","year":"2020","journal-title":"CJC Open"},{"key":"R100-20240830","doi-asserted-by":"crossref","first-page":"98","DOI":"10.14740\/cr1224","article-title":"Effect of ezetimibe added to high-intensity statin therapy on low-density lipoprotein cholesterol levels: A meta-analysis","volume":"12","author":"Lee","year":"2021","journal-title":"Cardiol Res"},{"key":"R101-20240830","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","article-title":"Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials","volume":"223","author":"Morrone","year":"2012","journal-title":"Atherosclerosis"},{"key":"R102-20240830","first-page":"415","article-title":"Ezetimibe therapy: Mechanism of action and clinical update","volume":"8","author":"Phan","year":"2012","journal-title":"Vasc Health Risk Manag"},{"key":"R103-20240830","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"R104-20240830","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.jacc.2021.08.011","article-title":"Baseline low-density lipoprotein cholesterol and clinical outcomes of combining ezetimibe with statin therapy in IMPROVE-IT","volume":"78","author":"Oyama","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R105-20240830","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"key":"R106-20240830","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"R107-20240830","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N Engl J Med"},{"key":"R108-20240830","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: Insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"key":"R109-20240830","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.amjmed.2020.03.056","article-title":"A meta-analysis assessing additional LDL-C reduction from addition of a bile acid sequestrant to statin therapy","volume":"133","author":"Alder","year":"2020","journal-title":"Am J Med"},{"key":"R110-20240830","first-page":"61","article-title":"Patient adherence and preference considerations in managing cardiovascular risk: Focus on single pill and amlodipine\/atorvastatin fixed combination","volume":"3","author":"Aslam","year":"2009","journal-title":"Patient Prefer Adherence"},{"key":"R111-20240830","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3390\/pharmaceutics12020190","article-title":"Does the polypill improve patient adherence compared to its individual formulations? A systematic review","volume":"12","author":"Baumgartner","year":"2020","journal-title":"Pharmaceutics"},{"key":"R112-20240830","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s10741-019-09874-2","article-title":"Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: A systematic review","volume":"25","author":"Azari","year":"2020","journal-title":"Heart Fail Rev"},{"key":"R113-20240830","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s41669-021-00300-8","article-title":"Cost-effectiveness analysis of evolocumab for the treatment of dyslipidemia in the Kingdom of Saudi Arabia","volume":"6","author":"Alghamdi","year":"2022","journal-title":"Pharmacoecon Open"},{"key":"R114-20240830","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"R115-20240830","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: A scientific statement from the American Heart Association","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circulation"},{"key":"R116-20240830","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jfma.2016.11.013","article-title":"2017 Taiwan lipid guidelines for high risk patients","volume":"116","author":"Li","year":"2017","journal-title":"J Formos Med Assoc"},{"key":"R117-20240830","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2165\/11208090-000000000-00000","article-title":"Fenofibrate: A review of its use in dyslipidaemia","volume":"71","author":"McKeage","year":"2011","journal-title":"Drugs"},{"key":"R118-20240830","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.atherosclerosis.2006.02.012","article-title":"Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: A systematic review","volume":"189","author":"Balk","year":"2006","journal-title":"Atherosclerosis"},{"key":"R119-20240830","doi-asserted-by":"crossref","first-page":"e013543","DOI":"10.1161\/JAHA.119.013543","article-title":"Marine Omega-3 supplementation and cardiovascular disease: An updated meta-analysis of 13 randomized controlled trials involving 127 477 participants","volume":"8","author":"Hu","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R120-20240830","first-page":"359","article-title":"Cumulative non-HDL-cholesterol burden in patients with hypertriglyceridemia receiving long-term fibrate therapy: Real life data from a lipid clinic cohort","volume":"48","author":"Kay\u0131k\u00e7\u0131o\u011flu","year":"2020","journal-title":"Turk Kardiyol Dern Ars"},{"key":"R121-20240830","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/1475-2840-11-125","article-title":"Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction","volume":"11","author":"Tenenbaum","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"R122-20240830","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12933-021-01291-w","article-title":"Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: A pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials","volume":"20","author":"Yokote","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"R123-20240830","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3390\/jcm11030768","article-title":"The Effect of fibrates on kidney function and chronic kidney disease progression: A systematic review and meta-analysis of randomised studies","volume":"11","author":"Hadjivasilis","year":"2022","journal-title":"J Clin Med"},{"key":"R124-20240830","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/17512433.2018.1537780","article-title":"Benefits and risks of the treatment with fibrates \u2013 A comprehensive summary","volume":"11","author":"Okopie\u0144","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R125-20240830","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/14779072.2020.1768848","article-title":"Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia","volume":"18","author":"Nurmohamed","year":"2020","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R126-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"key":"R127-20240830","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1001\/jama.2018.2525","article-title":"Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: A systematic review and meta-analysis","volume":"319","author":"Navarese","year":"2018","journal-title":"JAMA"},{"key":"R128-20240830","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"R129-20240830","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N Engl J Med"},{"key":"R130-20240830","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Journal of Research in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jrms.jrms_318_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:28:01Z","timestamp":1787768881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jrms.jrms_318_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":129,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jrms.jrms_318_23","relation":{},"ISSN":["1735-1995","1735-7136"],"issn-type":[{"value":"1735-1995","type":"print"},{"value":"1735-7136","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"2023-05-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}